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In recent times, antiepileptic drug (AED) development has expanded with at least seven new AEDs being 
marketed in a variety of countries. However, in this same period there have been very few trials of new AEDs in 
the developing world where the majority of people with epilepsy reside. There are many problems with the 
extrapolation of results from AED trials in developed countries, thus underlining the need for new AED trials in 
developing countries. This, however, presents a number of ethical and logistical problems, as the majority of people 
with epilepsy in developing countries are inadequately treated with established drugs. Additionally, there are 
further problems involving the cost of treatment and the allocation of sparse resources. If trials of new AEDs are 
to take place in developing countries, strict ethical guidelines must be adhered to, the trials must not be purely 
marketing exercises, and there must be the continued availability of the new AED to those in the trials who have 
benefited. 
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INTRODUCTION 
In a medline review of articles on new antiepilep- 
tic drugs (AEDs) published over the last five 
years, we were only able to identify two trials that 
had taken place in developing countries. One of 
these trials was a double-blind study of progabide 
as add-on in refractory epilepsy in Uruguay’, the 
other was a ‘field study’ of vigabatrin in Brazil*. 
There was one further trial of vitamin E in India, 
which was a double-blind add-on trial showing no 
advantage of vitamin E over placebo3. In this 
same period at least seven new antiepileptic 
drugs-felbamate, gabapentin, lamotrigine, ox- 
carbazepine, progabide, vigabatrin and 
zonisamide-have been licensed around the 
world (including developing countries). This lack 
of reported trials of new AEDs in developing 
countries raises a number of questions, particu- 
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larly as the majority of patients with epilepsy 
world-wide are in the so-called third world 
countries. Unreported trials of new AEDs are 
taking place, but these trials are not subject to 
international scrutiny, and, as will be seen, this 
presents its own problems, as some of these trials 
may be no more than marketing ploys. There are 
several considerations in deciding whether AED 
trials, particularly of novel compounds, should be 
carried out in developing countries. The first is to 
address the magnitude of the problem of epilepsy 
in developing countries in terms of its epidemiol- 
ogy, response to treatment and social impact. The 
second consideration is the extent to which results 
from AED trials in developed countries can be 
extrapolated to developing countries. The third 
consideration is the logistics of carrying out AED 
trials in developing countries, and lastly there are 
the ethical aspects of drug trials in developing 
countries. 
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EPILEPSY IN DEVELOPING COUNTRIES- 
MAGNITUDE OF THE PROBLEM 
It is generally accepted that the incidence of 
epilepsy in the developed world is around 
50/1000OO/year. There have been few satisfac- 
tory studies of incidence rates of epilepsy in 
developing countries. Only five studies have 
reported incidence rates and these have varied 
between 35/1OOOOO/year in China4 and 
230/100 OOO/year in Ecuado?. A rate of 
73/1OOOOO/year has been reported from 
Tanzania6 but there was a large intra-regional 
variation. A rate of 114/100 OOO/year from Chile’ 
and between 122 and 190/100000/year from an 
Andean region of Ecuador’ have been reported. 
Thus, apart from the results of the Chinese study, 
all other studies in developing countries suggest a 
higher incidence of epilepsy than in developed 
countries. There are more data available on 
prevalence rates of epilepsy than on incidence. 
The former are more easily obtained than the 
latter as smaller numbers are needed and 
cross-sectional designs can be used. There are 
large variations in the prevalence rates reported 
from the developing world from rates as low as 
2.3/1000g to as high as 57/100010. Most surveys 
have, however, reported rates within a much 
narrower band, 4.4 to 19/100011-14. Large reliable 
population-based studies have been in the lower 
end of the spectrum15. Studies in the upper end 
of the spectrum are usually small scale surveys 
in geographic isolates and thus should be 
treated with caution”. If prevalence rates are 
higher in developing countries, this probably 
relates to the younger age of the populations, the 
different aetiological profiles, and socioeconomic 
factors16. 
Studies in four developing countries, Ecuador, 
Kenya, the Philippines and Pakistan, have shown 
that only a small proportion of patients (8-20%) 
with active epilepsy is at any one time actually 
receiving drug treatment16. Yet, in both the 
developed and developing world, control of 
seizures with monotherapy with a variety of 
AEDs can be achieved in about 60-80% of 
patients”. This, however, still leaves approxim- 
ately 20% who require polytherapy, and a large 
proportion of these will be resistant to present 
AEDs. Furthermore side-effects are a major 
cause for the failure of treatment”, and thus new 
AEDs that have better side-effect profiles may be 
better tolerated. It has been assumed that 
side-effects are not such an important issue in 
developing countries, but this is probably a 
misconceived perception16. 
The social impact of epilepsy in the developed 
world is without question large, and indeed the 
indirect cost of epilepsy to society far outweighs 
the medical cost’*. In developing countries the 
social impact of epilepsy is also great. The social 
stigma, the inability of people with poorly 
controlled epilepsy to work, the hazards (in some 
countries epilepsy is called the ‘burn disease’) and 
the social disadvantages are probably even more 
important than in the developed world16. The 
indirect cost, however, is likely to be smaller 
whilst the medical costs of drug treatment are 
likely to be similar. In some cases medical costs 
may exceed the indirect social costs. Thus 
although in developing countries, hospital and 
clinical studies have shown that epilepsy is one of 
the commonest problems seen in outpatient 
clinicslg, epilepsy, as with other chronic diseases, 
generally carries a low priority for health care 
provision, which tends to be directed to acute, 
infectious and more life threatening conditions. 
Thus it is necessary to show that medical 
intervention for epilepsy can be successful and 
improve quality of life for scarce resources to be 
allocated2’. 
EXTRAPOLATION OF TRIALS FROM THE 
DEVELOPED WORLD 
Efficacy 
Although well-studied in the developed world, 
there have been few carefully monitored, pros- 
pective studies of AED efficacy in the developing 
world. This is important as many people with 
epilepsy in developing countries have had their 
condition for long periods before treatment is 
made available, a situation very different from 
that in most developed countries, with well- 
developed health economies21”2. It has been 
proposed that patients whose epilepsy is 
left untreated will become increasingly 
intractable”*24, and thus that patients in the 
developing world may prove to be more refrac- 
tory than those in the developed world. This does 
not, however, appear to be the case, and the 
response to treatment of previously untreated 
populations in the developing world is probably 
similar to that in the developed world21,“. 
Another aspect that can affect the response of 
epilepsy to antiepileptic drugs is the different 
spectrum of aetiologies of epilepsy in the 
developing world. This is especially so for 
infectious causes, which are commoner in de- 
veloping countries “jJ5. Because of the lack of 
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diagnostic tools and manpower in developing 
countries, these causes are not always identified, 
yet may greatly affect the prognosis and response 
to treatment of the epilepsy. For example, it has 
been suggested that epilepsy due to cystercercosis 
(a common cause of epilepsy in the developing 
world) responds well to treatment with cysticidal 
therapy, but those who do not receive this 
therapy have a poor response to AED 
treatment26T27. At present, new AED trials in 
developed countries are carried out in patients 
classified by the type of seizure, and subdivision 
by aetiology is avoided. Thus, these trials should 
not be extrapolated to developing countries in 
which there is a different spread of aetiologies 
with possibly different responses to AED 
treatment. 
Side-effects 
The side-effects of AEDs consist of those that are 
objectively reported by the physician (e.g. ataxia, 
nystagmus) and those that are subjectively 
reported by the patient (e.g. unsteadiness, drow- 
siness). In most drug trials, it is the latter that 
make up most of the reported adverse events. 
The emphasis laid upon many side-effects is 
dependent upon social and cultural influences, 
and thus would be expected to differ from one 
community to another and from rural to urban 
societies. 
There are also genetic and dietary influences in 
the incidence of specific side-effects. This has 
been well documented for zonisamide. Trials of 
zonisamide were abandoned in Europe and the 
U.S.A. due to a high incidence of kidney stones 
(4%), yet this side-effect has been seen in only 
one of over 2000 patients treated in Japan*‘. 
Pharmacokinetics 
The pharmacokinetics of AEDs can be influenced 
by both genetic and environmental factors. 
Genetic polymorphism has been well described 
for the metabolism of phenytoin, and as a result 
phenytoin kinetics may not only vary from 
country to country, but even in sub-populations 
within one country*‘“‘. Furthermore different 
formulations available in different countries can 
also affect the pharmacokinetics31. Other factors 
that play a prominent role are the prevalence of 
renal and hepatic diseases which affect the 
elimination of drugs, and gastrointestinal disease 
which affects the absorption. Furthermore popu- 
lation pharmacokinetics are partly determined by 
the age range and spread of that population (for 
example the clearance of gabapentin decreases 
with age due to an age-related decrease in 
creatinine clearance3*. The age range and spread 
of populations in developing countries are very 
different from those in developed countries16. 
PROBLEMS OF DRUG TRIALS IN 
DEVELOPING COUNTRIES 
Recruitment and running a drug trial 
The recruitment of patients into AED trials is 
likely to encounter many problems. As previously 
mentioned, the majority of patients in the 
developing world are not receiving AED therapy. 
The reasons for this failure of treatment are 
complex, and may involve non-pharmacological 
aspects such as cultural attitudes to epilepsy, 
acceptability of drugs for treatment, the cost of 
treatment, and less well-developed systems for 
the delivery of health care. All these will similarly 
affect patient recruitment to AED trials, but the 
last point has even wider implications. In most 
developing countries there is a chronic lack of 
trained medical manpower, and this is more 
noticeable in rural areas. A recurring recommen- 
dation to cope with this is to use health workers to 
treat patients at a community health care 
leve133”5. This could lead to problems in correctly 
diagnosing epilepsy, determining the type of 
epilepsy and the aetiology. This problem is 
further compounded by the lack of imaging and 
EEG facilities in these countries. 
Furthermore, it is incorrect to consider a 
country as a homogeneous group of people, and 
nowhere is this emphasized more than in the 
developing countries where there is often a great 
divide between rich and poor not only in terms of 
money and education but also occasionally in 
terms of race. Antiepileptic drug trials carried out 
in these countries are more likely to involve the 
rich minority than the poor majority, both for 
logistical and political reasons. 
Ethics 
The first and foremost ethical consideration is the 
criteria that should be used for inclusion in trials 
of new AEDs. The criteria that are used in the 
developing world should be the same as those in 
the developed world, and initially new AEDs 
should only be tried as add-on in patients with 
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epilepsy that is resistant to available AEDs. This, 
however, immediately presents a logistical prob- 
lem in that the majority of AEDs commonly 
available in developed countries are not acces- 
sible in developing countries. Thus the restriction 
that must apply is that the epilepsy is resistant to 
AEDs that are accessible in the country in which 
the trial is taking place. Developing countries do, 
however, present a good opportunity to try new 
AEDs in drug-ndive patients*‘, but ethically, this 
should only be done with those drugs that have 
reached a similar stage in developed countries. 
Another problem is the expense of the drug. It 
is unethical to withdraw a new AED that has 
been very effective in a patient entered into a 
drug trial. In most drug trials, patients who have 
responded to a new AED can continue that drug 
in continuation trials or on a named patient basis, 
and when the drug is licensed the drug is usually 
then paid for by the health care system of that 
country. In developing countries, it is un- 
reasonable to expect underfunded health care 
systems to finance the continuation of a new and 
expensive AED by patients entered into trials. 
This expense should be entirely met by the drug 
company funding the research for the period that 
the drug remains efficacious in each patient (for 
life, if necessary). This is paramount if short-term 
‘trials’ of new AEDs that are just used to sell the 
AED to the participating patients are to be 
avoided. The expense of new AEDs has wider 
implications. Only the minority of patients with 
active epilepsy in the developing world are 
receiving AED treatment, and it is likely that 
education and improved resources would greatly 
affect the prognosis of epilepsy in these 
communities*‘. Within this context, the use of 
newer more expensive AEDs is difficult to justify. 
Although in developed countries the indirect 
costs of epilepsy far outweighs the costs of 
medical treatmenti8, in financial terms in de- 
veloping countries this may not be the case and is 
most certainly not the case when considering the 
use of new AEDs for which the cost of a year’s 
treatment may exceed the national average wage. 
This calls into question the whole concept of 
AED trials especially trials of new AEDs in 
developing countries, as, regardless of the finding 
of these trials, the AEDs may not be affordable. 
Furthermore, the use of limited resources by 
governments in the developing world to fund 
AEDs that may have marginal benefits over much 
cheaper established AEDs such as phenobar- 
bitone or phenytoin should perhaps have less 
priority than the use of these resources to tackle 
the preventable causes of epilepsy or the distribu- 
tion of AEDs. Unless the newer AEDs are made 
available to the developing world at a con- 
siderable discount, it is difficult to justify the 
distribution of new AEDs to those countries 
regardless of the results of these trials. 
CONCLUSIONS 
The developing world contains a large population 
of people with epilepsy, most of whom are 
inadequately treated. Yet even given AED 
treatment, there will still be a significant number 
who are resistant to established AEDs. There is 
thus a need for new AED development in these 
countries. Because of the different demographics 
and aetiologies of the epilepsies, the results of 
new AED trials from the developed world cannot 
be simply extrapolated to the developing world, 
and thus drug trials are necessary. There are, 
hpwever, many logistical and ethical problems in 
carrying out these trials. Eventually, the problem 
of expense remains, and this is the dichotomy- 
AED trials in developing countries are on the one 
hand necessary for improved treatment in these 
countries, especially since surgical treatment is 
not available, and on the other hand, new AEDs 
cannot be afforded by these countries. 
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